Russell Schundler, serving as General Counsel for Liquidia Corp (NASDAQ: LQDA), executed a significant divestment of company equity on July 13, 2026. The transaction involved the sale of 14,738 shares of common stock, generating a total proceeds value of $1,053,925. The execution price for these shares ranged between $71.39 and $71.52 per unit. Crucially, these sales were not ad-hoc but were conducted pursuant to a Rule 10b5-1 trading plan that Mr. Schundler established on December 15, 2023. The primary financial driver for this liquidity event was the need to cover tax liabilities associated with the settlement of restricted stock units and performance stock units.
Before this divestment, Mr. Schundler had acquired 10,168 shares of common stock on July 10, 2026. These shares were obtained through the conversion of performance stock units, which convert into common stock on a one-for-one basis. The underlying units included 3,759 units granted on January 11, 2024, and 6,409 units granted on January 11, 2025, which had vested as of the report date. Following these transactions, Mr. Schundler directly holds 605,962 shares of Liquidia Corp common stock. This total includes 13,021 unvested RSUs from a January 2023 grant, 41,300 unvested RSUs from a January 2024 grant, 64,089 unvested RSUs from a January 2025 grant, 32,955 unvested RSUs from a January 2026 grant, and 12,306 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Additionally, Mr. Schundler indirectly holds 14,500 shares through his spouse, though he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Liquidia Corp's financial profile presents a robust operational foundation. The company reports a gross profit margin of 92% and has demonstrated profitability over the last twelve months. The stock has shown significant upward momentum, climbing to $76.47, which reflects a 427% return over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with 18 additional ProTips available to subscribers.
In other recent developments, Liquidia Corporation has reported several notable shifts in market positioning and investor outlook. BofA Securities downgraded Liquidia's stock rating from Buy to Neutral but raised the price target from $64 to $79. This decision followed the company's drug, Yutrepia, surpassing sales expectations, leading BofA to increase its peak sales estimate to $2.2 billion. Similarly, H.C. Wainwright raised its price target for Liquidia to $75, maintaining a Buy rating, due to favorable legal outcomes related to a Supreme Court ruling. Raymond James reiterated a Strong Buy rating with a price target of $68, also citing positive implications from the same legal decision.
Furthermore, Liquidia is set to join the S&P SmallCap 600 Index, effective June 22. This inclusion reflects the company's market capitalization, liquidity, and profitability metrics. The S&P SmallCap 600 Index tracks 600 small-cap U.S. companies based on specific criteria. These recent updates highlight significant shifts in Liquidia's market positioning and investor outlook.